Figure S1. Viability in H295R cells treated with rosuvastatin. Viability of rosuvastatin-treated H295R cells. Cell viability was measured by WST1 assay. Results are the means ± SEM of 8 to 32 independent determinations from 3 different experiments. (A) H295R cells were treated for 24, 48 and 72 h with rosuvastatin (100 μM; R100). (B) H295R cells were treated with increasing concentrations of rosuvastatin. Data are the means ± SEM of 8 to 32 independent determinations from 3 different experiments. ***P<0.0001 vs. control (DMSO).



Figure S2. Viability of H295R cells treated with mitotane and/or rosuvastatin at 72 h. Cell viability in mitotane and/or rosuvastatin-treated H295R cells. H295R cells were treated for 72 h with mitotane (50 μM or 100 μM), rosuvastatin (100 μM), alone or in combination. Cell viability was measured by WST1 assay. Results are the means ± SEM of 8 to 16 independent determinations from 2 different experiments. Data are the means ± SEM of 8 to 32 independent determinations from 3 different experiments. *P<0.05, **P<0.01 and ***P<0.001 vs. control (DMSO); ns, not significant.



Figure S3. Steroidogenesis in H295R cells treated with mitotane and/or rosuvastatin. H295R cells were treated for 48 h with mitotane (25 μM; M25), rosuvastatin (50 μM; R50) alone or in combination (R50M25). Steroid concentrations in cell supernatants were measured by LC-MS/MS and are expressed in ng/ml. (A) Cortisol concentration; (B) corticosterone concentration. Data are the means ± SEM of 4 independent determinations. *P<0.05 vs. control (FC or BC); NS, not significant. FC, cortisol control; FM25, cortisol mitotane 25 μM; FR50, cortisol rosuvastatin 50 μM; FR50M25, cortisol rosuvastatin 50 μM and mitotane 25 μM; BC, corticosterone control; BM25, corticosterone mitotane 50 μM; BR50, corticosterone rosuvastatin 50 μM; BR50M25, corticosterone rosuvastatin 50 μM and mitotane 25 μM.



Table SI. Primer sequences.

Gene	Amplicon size (bp)	Sense primer	Antisense primer
HMGCR	119	5'-GGACCAACCTACTACCTCAGCAA-3'	5'-CCATTACGGTCCCACACACA-3'
ABCA1	67	5'-CCCTCATTCCAAGCACTTTACG-3'	5'-CAATTCTCAGATATTCCAGTGCAAA-3'
CYP11A1	149	5'-CGATTACCGTGGCATCCTCTA-3'	5'-AGGTTGCGTGCCATCTCATAC-3'
StAR	121	5'-GCCACAGACTTCGGGAACAT-3'	5'-AGTAGCCACGTAAGTTTGGTCTTAGAG-3'
18S	71	5'-GTGCATGGCCGTTCTTAGTTG-3'	5'-CATGCCAGAGTCTCGTTCGTT-3'
36B4	75	5'-AGCGCGTCCTGGCATTGTCTGT-3'	5'-GGGCAGCAGTGGTGGCAGCAGC-3'

bp, base pairs.